Market Overview:
The global hyperlipidemia prescription drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into HMG COA reductase inhibitors, fibric acid derivatives, nicotinic acid, bile acid sequestrating agents and cholesterol absorption inhibitors. The HMG COA reductase inhibitors segment dominates the global hyperlipidemia prescription drugs market with a share of more than 50%. This can be attributed to factors such as high prevalence of hyperlipidemia and rising awareness about available treatment options among patients. On the basis of application, hospital accounts for majority share in terms of revenue in 2017 and this trend is expected to continue during the forecast period as well.
Product Definition:
Hyperlipidemia is a disorder of lipid metabolism that is characterized by an elevation in the levels of lipids in the blood. This can lead to the development of atherosclerosis, heart disease, and other serious health problems. Hyperlipidemia can be treated with prescription drugs that help to lower lipid levels. These medications are important for preventing and treating the serious health consequences of this condition.
HMG COA Reductase Inhibitors:
Hyperlipidemia is a condition where there is an excessive amount of lipids in the blood. Hyperlipidemic patients are expected to take high doses of HMG CoA Reductase Inhibitors (statins) for the treatment course which may or may not be effective.
Fibric Acid Derivatives:
Fibric acid derivatives are a group of drugs that reduce elevated levels of certain types of lipids in the blood. Elevated lipid levels are linked to increased risk for cardiovascular diseases and other chronic conditions. Fibric acid derivatives lower triglyceride and cholesterol levels by inhibiting the enzyme that makes them form clots in the blood vessels, thereby reducing the risk for CVDs.
Application Insights:
Hyperlipidemia finds application in the treatment of various diseases as it is a result of improper digestion and absorption of lipids by the body. The major applications include hospital-based and non-hospital based clinics. Hospital-based hyperlipidemia prescription drugs market is expected to grow at a CAGR of XX% over the forecast period owing to increasing prevalence, which has resulted in increased demand for effective treatment options.
Non-hospital based clinics are expected to witness growth due to rising awareness regarding lifestyle modifications that can prevent or cure chronic diseases such as cardiovascular disease, diabetes mellitus type 2, cancer, etc. Furthermore, growing incidence rate for these disorders coupled with rising healthcare expenditure will boost product demand in non hospital based clinics over the forecast period.
The other segment includes retail pharmacies.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of key players, high treatment cost and availability of insurance coverage for Hyperlipidemia drugs. In addition, increasing prevalence levels and rising consumer awareness about these conditions are also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving economic status, growing population base along with an increase in healthcare expenditure & government initiatives for disease management & prevention.
Growth Factors:
- Increasing prevalence of hyperlipidemia: The global prevalence of hyperlipidemia is increasing at a rapid pace. This is primarily attributed to the changing lifestyle and dietary habits of people across the world. This is expected to drive the demand for hyperlipidemia prescription drugs in the coming years.
- Growing awareness about hyperlipidemia: There is a growing awareness among people about the risks associated with high levels of lipids in blood. This is likely to boost demand for hyperlipidemia prescription drugs in the near future.
- Technological advancements in drug development: The pharmaceutical industry is witnessing significant advancements in drug development technologies, which are helping researchers develop better and more effective treatments forhyperlipidemiasuch as statins and fibrates etc.).Thisisexpectedtodrivethegrowthofthehyperlipidemiaprescriptiondrugsmarketinthecomingyears.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hyperlipidemia Prescription Drugs Market Research Report
By Type
HMG COA Reductase Inhibitors, Fibric Acid Derivatives, Nicotinic Acid, Bile Acid Sequestrating Agents, Cholesterol Absorption Inhibitors, Combination Drug Therapy
By Application
Hospital, Clinic
By Companies
Amgen, Eli Lilly, GlaxoSmithKline Pharmaceuticals, Isis Pharmaceuticals, Merck, Dr.Reddy's Laboratories, Immuron Limited, Esperion Therapeutics, Pfizer, Formac Pharmaceuticals, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
132
Number of Tables & Figures
93
Customization Available
Yes, the report can be customized as per your need.
Global Hyperlipidemia Prescription Drugs Market Report Segments:
The global Hyperlipidemia Prescription Drugs market is segmented on the basis of:
Types
HMG COA Reductase Inhibitors, Fibric Acid Derivatives, Nicotinic Acid, Bile Acid Sequestrating Agents, Cholesterol Absorption Inhibitors, Combination Drug Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Eli Lilly
- GlaxoSmithKline Pharmaceuticals
- Isis Pharmaceuticals
- Merck
- Dr.Reddy's Laboratories
- Immuron Limited
- Esperion Therapeutics
- Pfizer
- Formac Pharmaceuticals
- Amgen
Highlights of The Hyperlipidemia Prescription Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HMG COA Reductase Inhibitors
- Fibric Acid Derivatives
- Nicotinic Acid
- Bile Acid Sequestrating Agents
- Cholesterol Absorption Inhibitors
- Combination Drug Therapy
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hyperlipidemia Prescription Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hyperlipidemia is a condition in which there is an excess of lipids (fats) in the blood. This can be caused by a number of factors, including obesity, genetics, and lifestyle choices. Hyperlipidemia can lead to heart disease, stroke, and other serious health problems. Prescription drugs are medications that are prescribed by a doctor to treat specific conditions. Some prescription drugs used to treat hyperlipidemia include statins (such as atorvastatin or simvastatin), niacin (a type of vitamin B3), and fibrates (such as gemfibrozil or clofibrate).
Some of the key players operating in the hyperlipidemia prescription drugs market are Amgen, Eli Lilly, GlaxoSmithKline Pharmaceuticals, Isis Pharmaceuticals, Merck, Dr.Reddy's Laboratories, Immuron Limited, Esperion Therapeutics, Pfizer, Formac Pharmaceuticals, Amgen.
The hyperlipidemia prescription drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hyperlipidemia Prescription Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hyperlipidemia Prescription Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hyperlipidemia Prescription Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hyperlipidemia Prescription Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hyperlipidemia Prescription Drugs Market Size & Forecast, 2020-2028
4.5.1 Hyperlipidemia Prescription Drugs Market Size and Y-o-Y Growth
4.5.2 Hyperlipidemia Prescription Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 HMG COA Reductase Inhibitors
5.2.2 Fibric Acid Derivatives
5.2.3 Nicotinic Acid
5.2.4 Bile Acid Sequestrating Agents
5.2.5 Cholesterol Absorption Inhibitors
5.2.6 Combination Drug Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hyperlipidemia Prescription Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hyperlipidemia Prescription Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 HMG COA Reductase Inhibitors
9.6.2 Fibric Acid Derivatives
9.6.3 Nicotinic Acid
9.6.4 Bile Acid Sequestrating Agents
9.6.5 Cholesterol Absorption Inhibitors
9.6.6 Combination Drug Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 HMG COA Reductase Inhibitors
10.6.2 Fibric Acid Derivatives
10.6.3 Nicotinic Acid
10.6.4 Bile Acid Sequestrating Agents
10.6.5 Cholesterol Absorption Inhibitors
10.6.6 Combination Drug Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 HMG COA Reductase Inhibitors
11.6.2 Fibric Acid Derivatives
11.6.3 Nicotinic Acid
11.6.4 Bile Acid Sequestrating Agents
11.6.5 Cholesterol Absorption Inhibitors
11.6.6 Combination Drug Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 HMG COA Reductase Inhibitors
12.6.2 Fibric Acid Derivatives
12.6.3 Nicotinic Acid
12.6.4 Bile Acid Sequestrating Agents
12.6.5 Cholesterol Absorption Inhibitors
12.6.6 Combination Drug Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 HMG COA Reductase Inhibitors
13.6.2 Fibric Acid Derivatives
13.6.3 Nicotinic Acid
13.6.4 Bile Acid Sequestrating Agents
13.6.5 Cholesterol Absorption Inhibitors
13.6.6 Combination Drug Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hyperlipidemia Prescription Drugs Market: Competitive Dashboard
14.2 Global Hyperlipidemia Prescription Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Eli Lilly
14.3.3 GlaxoSmithKline Pharmaceuticals
14.3.4 Isis Pharmaceuticals
14.3.5 Merck
14.3.6 Dr.Reddy's Laboratories
14.3.7 Immuron Limited
14.3.8 Esperion Therapeutics
14.3.9 Pfizer
14.3.10 Formac Pharmaceuticals
14.3.11 Amgen
